Pegfilgrastim in children with severe congenital neutropenia.
Article Details
- CitationCopy to clipboard
Fioredda F, Calvillo M, Lanciotti M, Lanza T, Giunti L, Castagnola E, Lorenzi I, Tonelli R, Ghezzi P, Dufour C
Pegfilgrastim in children with severe congenital neutropenia.
Pediatr Blood Cancer. 2010 Mar;54(3):465-7. doi: 10.1002/pbc.22350.
- PubMed ID
- 19927291 [ View in PubMed]
- Abstract
Two pediatric patients affected by severe congenital neutropenia (SCN) were treated with 100 mcg/L/dose every 9-12 days within a pilot study (Observatory of the Italian Ministry of Health, Eudract Code 2005-003096-20) on the use of pegfilgrastim in patients with chronic neutropenia. Both children increased their absolute neutrophil count, reduced their infectious load, and improved their quality of life. Serum concentrations of G-CSF observed in pegfilgrastim mirrored those seen in filgrastim. These data suggest that pegfilgrastim may be beneficial in SCN patients with an exposure of hematopoietic cells to G-CSF similar to that on filgrastim.